Биоаналоги в онкологии: новые горизонты, старые проблемы

биоаналог, эритропоэтин, анемия, рак

1. Ross S.D., Fahrbach K., Frame D. et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786-805.

2. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Rev Drug Discov 2002;1:457-62.

3. Chen M.L., Shah V., Patnaik R. et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001;18:1645-50.

4. Crommelin D., Bermejo T., Bissig M. et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Science 2005; П(1):11-7.

5. Crommelin D. Differences between biopharmaceuticals and low-moleculare weight pharmaceuticals. Eur J Hosp Pharm 2003;8:74-6.

6. Dube S., Fisher J.W., Powell J.S. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 1988;263:17516-21.

7. Fukuda M.N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989;73:84-9.

8. Starring P.L., Gaines Das R.E. The International Standard for Recombinant DNA derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 1992;134:459-84.

9. Starring P.L., Tiplady R.J., Gaines Das R.E. et al. Lectin-binding assays for the isoforms of human erythropoietin: comparison of urinary and four recombinant erythropoietins. J Endocrinol 1996;150:401-12.

10. Gokana A., Winchenne J.J., Ben Ghanem A. et al. Chromatographic separation of recombinant human erythropoietin isoforms. J Chromatogr A 1997;791:109-18.

11. Yuen C.T., Starring P.L., Tiplady R.J. et al. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins pro-ducedusing different culture conditions and purification procedures.Br J Haematol 2003;121:511-26.

12. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003;19:430-2.

13. Schellekens H. Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Curr Med Res Opin 2003;19: 433-4.

14. Prabhakar S.S., Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia.Clin Nephrol 1997;47:331-5.

15. Bennett C., Luminari S., Nissenson A. et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-07.

16. DiPaolo B., Pennetti A., Nugent L., Venkat K. Monitoring impurities in biopharmaceuticals produced by recombinant technology. Pharm Sci Technol 1999;2:70-82.

17. Agencia Nacional de Vigilancia Sanitaria (ANVISA). Resolution No. 1.174. July 22, 2003.

18. Agencia Nacional de Vigilancia Sanitaria (ANVISA). Resolution No. 1.250. August 1, 2003.

19. Schmidt C.A., Ramos A.S., da Silva J.E.P. et al. Activity evaluation and characterization of recombinant human erythropoietin in pharmaceutical products. Arq Bras Endocrinol Metab 2003;47:183-9.

20. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:43-7.

21. Erythropoietin concentrated solutions. Pharmeuropa 14.1. Jan 2002;94-9.

22. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP/ICH/365/96). Note for guidance on specifications: test procedures and acceptance criteria for biotech-nological/biological products. March 24, 1999.

23. Singh A.K. Renal Division, Brigham and Women's hospital & Harvard Medical School, Boston, USA. World Congress of Nephrology. 21-25 April, 2007.

24. Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues - guidance on similar medicinal products containing recombinant erythropoietins [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf

25. World Health Organization (WHO). Substandard and counterfeit medicines. Fact Sheet No. 275. November, 2003.